Maxim downgraded Monopar Therapeutics to Hold from Buy.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MNPR:
- Monopar Tanks After Validive Fails Cancer Trial
- Monopar to Present at the Jefferies Radiopharma Innovation Summit
- Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
- Monopar completes interim analysis of Phase 2b/3 VOICE trial
- Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments